1. Home
  2. KOS vs GLPG Comparison

KOS vs GLPG Comparison

Compare KOS & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kosmos Energy Ltd. (DE)

KOS

Kosmos Energy Ltd. (DE)

HOLD

Current Price

$3.08

Market Cap

1.6B

Sector

Energy

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$27.91

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOS
GLPG
Founded
2003
1999
Country
United States
Belgium
Employees
N/A
452
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
KOS
GLPG
Price
$3.08
$27.91
Analyst Decision
Hold
Buy
Analyst Count
6
2
Target Price
$1.91
$36.50
AVG Volume (30 Days)
18.6M
141.7K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,288,352,000.00
N/A
Revenue This Year
$27.11
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.84
$24.74
52 Week High
$3.17
$37.78

Technical Indicators

Market Signals
Indicator
KOS
GLPG
Relative Strength Index (RSI) 63.08 31.88
Support Level $1.62 N/A
Resistance Level $3.09 $34.04
Average True Range (ATR) 0.15 0.50
MACD 0.02 0.05
Stochastic Oscillator 93.12 18.46

Price Performance

Historical Comparison
KOS
GLPG

About KOS Kosmos Energy Ltd. (DE)

Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: